ArticleThe American journal of case reports2025
Rare Presentation of Middle Ear Neuroendocrine Tumor: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: NET of the ear- up to date in diagnostic and therapeutic challenges.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Neuroendocrine tumors (NETs) of the middle ear are exceptionally rare, representing less than 2% of primary ear tumors in adults. These neoplasms originate from neuroendocrine cells within the middle ear cavity, posing significant diagnostic and therapeutic challenges. CASE REPORT We present a 27-year-old man with a 2-month history of left-sided hearing loss, tinnitus, and ear fullness. Comprehensive assessments, including tuning fork tests, pure tone audiometry, computed tomography (CT) scan of the temporal bone, and magnetic resonance imaging (MRI), were conducted. Differential diagnoses, included cholesteatoma and other middle ear masses, but chronic suppurative otitis media was not considered due to the intact tympanic membrane. Intraoperative findings revealed a pale pink mass encasing the ossicular chain, confirmed as a neuroendocrine tumor (CK [+], Syn [+++], CK18 [+], EMA [++], CD56 [-], CgA [+], Ki67 [2%+]) by immunohistochemistry. The tumor was excised via an endoscopic tympanotomy. Postoperative follow-up over 2 years showed no recurrence or metastasis, and the patient reported no significant hearing impairment affecting quality of life. CONCLUSIONS Middle ear neuroendocrine tumors require meticulous diagnostic workup and precise surgical intervention. This case adds to the limited body of evidence supporting that middle ear neuroendocrine tumors, although rare, can be managed effectively with tailored surgical approaches. Continued case reporting will be vital to enhance understanding and to refine treatment guidelines for optimal patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.